Public Citizen Letter Calls on Gilead to Relinquish Priority Review Voucher

Public Citizen letter to Gilead re: remdesivir PRV

Lawmakers’ intent in creating the medical countermeasure priority review voucher (PRV) program was to provide additional incentives to pharmaceutical manufacturers to encourage development of new drug and biological medical countermeasures. Gilead is already being handsomely compensated through remdesivir sales and is slated to recoup any investment it made in its development many times over, which was heavily subsidized by taxpayers. Provision of the PRV was clearly an unnecessary windfall to Gilead in addition to these already excessive revenues. Public Citizen’s letter calls on Gilead to relinquish the PRV granted to it upon the approval of remdesivir.